TTNP

TTNP - Titan Pharmaceuticals Inc Stock Price, Fair Value and News

$4.61 
Market Closed as of 02 Oct 2025, 04:00 pm ET

TTNP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TTNP Price Action

TTNP RSI Chart

TTNP Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TTNP Valuation

TTNP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TTNP Fundamentals

TTNP Revenue

TTNP Earnings

TTNP Profitability

TTNP Investor Care

Revenue & Growth

How Titan Pharmaceuticals Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2023463.5K396.5K304.5K184.0K
20221.0M741.0K572.0K557.5K
20214.4M3.6M2.8M1.5M
20202.8M3.5M3.6M4.8M
20195.5M4.3M3.6M2.6M
20181.2M3.8M4.8M6.6M
201711.4M7.6M3.9M215.0K
2016-15.8M15.0M15.1M
20153.6M3.5M2.6M1.7M
20146.2M4.9M3.6M3.6M
201311.0M11.9M12.8M10.5M
20124.4M5.1M5.3M7.1M
20118.6M8.0M5.4M4.1M
2010---10.1M
2009----
2008----
TTNP
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
 CEO
 WEBSITEtitanpharm.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES4